Main Article Content

Waseem Raja Memon
Mir Tahir Hussain Talpur
Noor Nabi
Mukhtiar Ahmed Abro


Hepatitis C, Diabetes Mellitus, Prevalence


Objective: This study aims to evaluate the prevalence of Hepatitis C among a cohort of 150 patients with diabetes mellitus (DM).

Study design: A cross-sectional study

Place and Duration: This study was conducted in People's University of Medical and Health Sciences for Women Nawabshah from June 2022 to June 2023

Methodology: A total of 150 patients, both male and female, aged between 24-65 years, with DM were included in the study. Data on patients' age, gender, BMI, residence, and educational attainment were collected after obtaining informed written consent. Hepatitis C was diagnosed using the Enzyme-Linked Immuno-Sorbent Assay (ELISA) method. The diagnostic criteria for DM were based on two fasting or random plasma glucose levels exceeding 126 mg/dL and 200 mg/dL, respectively. Patients were subsequently categorized as hypoglycemic, normal, or hyperglycemic based on their blood glucose levels. The data analysis was performed using SPSS version 26.

Results: Among the 150 patients with diabetes, 80 (53.3%) were females and 70 (46.7%) were males. The mean age of patients was 37.8±14.89 years, with a mean BMI of 25.4±7.3 kg/m². The majority of cases were from rural areas (60%), and 40% had urban residency. Of the patients, 44.66% were educated, while 55.33% were uneducated. Hepatitis C was found in 28% of patients, all of whom had DM II, with the majority being females (60%). Most patients (54.76%) had glycemic values in the 180 mg/dl range. In the Hepatitis C cases, 20% were aged between 24-35 years, 50% were between 36-45 years, and 30% were older than 45 years. Elevated levels of Serum Glutamic-Pyruvic Transaminase (SGPT) were observed in 80.95% of patients.

Conclusion: This study concludes that Hepatitis C infection was prevalent among 28% of patients, primarily associated with DM II cases. The majority of affected patients were females, and elevated SGPT levels were common in this population.

Abstract 102 | PDF Downloads 49


1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
2. World Health Organization (WHO). Hepatitis C. Geneva: World Health Organization; 2021.
3. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care. 2018;41(2):372-382.
4. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World Journal of Gastroenterology. 2006;12(42):6756-6765.
5. Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586.
6. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60(1):98-105.
7. Golabi P, Bush H, Younossi ZM. Treatment strategies for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinical Liver Disease. 2018;11(5):109-113.
8. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine. 2015;373(27):2608-2617.
9. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: Implications for therapy. Journal of Hepatology. 2003;39(6):1042-1048.
10. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
11. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831-844.
12. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-456.
13. Kim HS, Rotundo L, Yang JD, et al. Racial/ethnic disparities in the prevalence and awareness of Hepatitis C virus infection among U.S. adults, NHANES 2001-2016. PLoS One. 2020;15(5):e0233702.
14. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
15. Younossi ZM, Stepanova M, Nader F, et al. Nonalcoholic Steatofibrosis Independently Predicts Mortality in Nonalcoholic Fatty Liver Disease. Hepatology. 2019;70(2):536-547.
16. Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137(2):549-557.
17. Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69-78.
18. Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99-114.
19. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglit